Dec 18, 2019 3:00 pm EST Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
Jul 24, 2019 9:25 am EDT Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
Jan 7, 2019 8:39 am EST Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
Apr 9, 2018 8:00 am EDT Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
